Potential effect of Irisin on sarcopenia: a systematic review

• Published in: BMC musculoskeletal disorders Vol. 26; no. 1; pp. 520 - 11
• Main Authors: Chen, Yixiao, Qian, Min, Gao, Feng, Li, Guoqing, Peng, Kangzu, Sun, Qingnan, Sun, Yifei, Liu, Gang, Ge, Yufeng, Yang, Minghui, Wu, Xinbao
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 27.05.2025; BioMed Central; BMC
• Subjects: Aging; Animals; Atrophy; Bias; Biomarkers; Biomarkers - blood; Biomarkers - metabolism; Care and treatment; Diagnosis; Drug approval; Exercise - physiology; FDA approval; Fibronectins - metabolism; Fibronectins - therapeutic use; Frailty; Geriatrics; Health aspects; Homeostasis; Humans; Irisin; Laboratory animals; Medical Subject Headings-MeSH; Muscle proteins; Muscle, Skeletal - drug effects; Muscle, Skeletal - metabolism; Muscle, Skeletal - pathology; Musculoskeletal diseases; Musculoskeletal system; Older people; Post-menopause; Protein hormones; Proteins; Quality control; Quality of life; Sarcopenia; Sarcopenia - blood; Sarcopenia - diagnosis; Sarcopenia - drug therapy; Sarcopenia - metabolism; Skeletal muscle; Systematic review; Treatment; China; Irisin; Sarcopenia; Systematic review; Treatment

Sarcopenia, a progressive musculoskeletal disorder associated with aging, is characterized by the deterioration of muscle mass, strength, and physical performance. This condition significantly increases the risk of debilitating consequences including functional impairment, diminished life quality, a...